Healthy
Conditions
Keywords
healthy volunteer, research subjects, Immunostimulatory sequence (ISS), phase 1
Brief summary
The main purpose of this study is to assess the safety, tolerability, and biological activity of SD-101 compared with placebo in healthy male volunteers.
Detailed description
This is a Phase 1, randomized, single-blind, placebo-controlled study of five escalating dose levels of SD-101 in healthy male volunteers. The objectives of the study are to assess the safety, tolerability, pharmacokinetic profile, and pharmacodynamics of SD-101. Approximately 40 subjects will participate. Once subjects have been consented, screened, and assigned to one of the dose levels of SD-101, subjects will receive a single subcutaneous injection of either SD-101 or placebo (PBS) in a ratio of 6:2. Safety and tolerability will be evaluated by occurrence of adverse events, blood and urine laboratory tests, physical examination findings, vital signs , and electrocardiogram findings. Pharmacodynamics will be evaluated by levels of blood biomarkers and serum cytokines, and flow cytometric cell counts. Pharmacokinetics will be evaluated by levels of study drug in serum.
Interventions
DRUGSD-101
Single subcutaneous escalating dose
DRUGplacebo
placebo
Sponsors
Dynavax Technologies Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Signed, written, informed consent must be obtained from the subjects before any study-specific procedures are performed. * Subject must be male and 18 years of age or older. * Subject must be willing to submit to a urine drug screen and agree to abstain from alcohol, caffeine, and tobacco during the required stay in the Phase I Unit. * Subject must be willing to abide by the rules of the Phase 1 Unit. * Subjects whose sexual partners are of childbearing potential must agree to use an effective method of birth control (i.e., chemical contraceptives, barrier plus spermicide, intrauterine device) during the treatment phase and for 14 days post treatment. * Must be negative for Hepatitis B and C and human immunodeficiency virus (HIV).
Exclusion criteria
* Females. * Clinically significant active, acute, or chronic illness. * History of coagulation or bleeding disorders. * Clinically significant chronic or recent (within 21 days of dosing) acute gastrointestinal disorder with nausea, vomiting or diarrhea as a major symptom. * Received any vaccine within 3 weeks of study entry or plans to be vaccinated within 6 weeks after study injection. * History of significant cardiovascular or cerebrovascular disease. * History of evaluation for autoimmune disease including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma or thyroiditis. * Significant psychiatric illness that could potentially interfere with the assessments during this study. * Subjects who have had prior surgery or a major infection within 6 months of dosing. * History of medications within 7 days of dosing, except vitamins and/or minerals. * History of Gilbert's disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects with and the amplitude and timing of adverse events, proportion of subjects with and the grade and timing of abnormal lab values, and proportion of subjects with and timing of changes in physical exam findings and vital signs | Up to 7 days after dosing |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters | Up to 24 hours after dosing |
| Levels of serum cytokines | Up to 7 days after dosing |
| Levels of blood biomarkers (interferon-alpha inducible genes) | Up to 7 days after dosing |
Countries
United States
Outcome results
None listed